Article PDF first page preview

First page of Expanding the Genetic Landscape of RASopathies: Significance of Including NF1 in Targeted Panels

Introduction: RASopathies are genetic disorders linked to the Ras/MAPK signaling pathway, including Noonan syndrome and related conditions. These disorders have overlapping features and varied phenotypes, making diagnosis challenging. This study examines the clinical and genetic characteristics of RASopathies in pediatric patients to improve diagnostic accuracy and identify new pathogenic variants. Methods: A total of 23 patients, who were not related to each other and were clinically diagnosed with RASasopathy, participated in the study Patients underwent next- generation sequencing (NGS) panel analyses of 14 RASopathy genes. Results: Pathogenic variants were found in 18 out of 23 patients (78%). The most common mutations were in PTPN11 and SOS1. Novel mutations were identified in RAF1, KRAS, and NF1, expanding the known genetic spectrum. Frequent clinical features included distinctive facial features, growth delays, and heart defects, notably pulmonary stenosis. Intellectual disability was more common in patients with PTPN11 variants, while SOS1 mutations were linked to unique features like previously unreported polydactyly and choanal atresia. Conclusion: Targeted NGS panels improve diagnosis of RASopathies, with a mutation detection rate of 78%. Including the NF1 gene, even without signs of neurofibromatosis, enhances diagnostic success. This study adds to our understanding of genotype-phenotype relationships in RASopathies and highlights new clinical features tied to SOS1 mutations. Comprehensive genetic testing supports earlier and more personalized care for patients with RASopathies.

Journal Section:
Research Article
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.